Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Evommune, Inc. (EVMN)

Evommune says EVO301 met Phase 2a primary endpoint in atopic dermatitis trial

Positive Impact 3 of 5 other Written later

Evommune presented late-breaking Phase 2a proof-of-concept data for its experimental drug EVO301 in moderate-to-severe atopic dermatitis at a European dermatology congress. The company said the drug met the trial's primary endpoint and plans to start a Phase 2b dose-ranging trial in mid-2027, a step that will take more time and money before any approval is possible.

Key points

  • Week 12 EASI reduction was 55% for EVO301 versus 22% on placebo (p<0.01), in a 70-patient trial
  • Treatment-related adverse events occurred in 10.4% of EVO301 patients versus 13.6% on placebo
  • Company plans to initiate a subcutaneous Phase 2b dose-ranging trial in mid-2027

The filing

CompanyEvommune, Inc. (EVMN)
Form8-K, current report
Filed with the SECOct 1, 2026, 8:01 AM ET
Accession number0001193125-26-409865

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.